

## Original Article

## Sardasht-Iran Cohort Study of Chemical Warfare Victims: Design and Methods

Tooba Ghazanfari PhD<sup>1,2</sup>, Soghrat Faghihzadeh PhD<sup>3</sup>, Hassan Aragizadeh MD<sup>4</sup>,  
 Mohammad-Reza Soroush MD<sup>5</sup>, Roya Yaraee PhD<sup>1,2</sup>, Zuhair Mohammad Hassan PhD<sup>6</sup>,  
 Abbas Foroutan MD PhD<sup>7</sup>, Mohammad-Reza Vaez-Mahdavi PhD<sup>8</sup>, Mohammad-Ali Javadi MD<sup>9</sup>,  
 Sakine Moaiedmohseni MD MPH<sup>10</sup>, Fereidoun Azizi MD<sup>11</sup>, Yunes Panahi PhD<sup>12</sup>,  
 Ali Mostafaie PhD<sup>13</sup>, Hassan Ghasemi MD<sup>14</sup>, Jalaeddin Shams MD<sup>15</sup>, Shahryar Pourfarzam MD<sup>16</sup>,  
 Mohammad-Reza Jalali-Nadoushan PhD<sup>17</sup>, Faramarz Fallahi MD<sup>18</sup>, Massoumeh Ebtekar PhD<sup>6</sup>,  
 Seyyed-Masoud Davoudi MD<sup>12</sup>, Zeinab Ghazanfari MSc<sup>19</sup>, Sussan K. Ardestani PhD<sup>20</sup>,  
 Shamsa Shariat-Panahi MD<sup>21</sup>, Athar Moin MD<sup>22</sup>, Abbas Rezaei PhD<sup>23</sup>, Amina Kariminia MD<sup>24</sup>,  
 Soheila Ajdary PhD<sup>24</sup>, Mahmoud Mahmoudi PhD<sup>25</sup>, Rasoul Roshan MD<sup>26</sup>,  
 Sulayman Ghaderi MSc<sup>27</sup>, Mahmoud Babai MD<sup>4</sup>, Mohammad-Mehdi Naghizadeh MSc<sup>2</sup>,  
 Mostafa Ghanei MD<sup>12</sup>, and the Sardasht-Iran Cohort Study Research Group\*

**Background:** Insights into long-term clinical consequences of sulfur mustard have emerged from some investigations but less is known about the basic and molecular mechanisms of these complications. Sardasht-Iran Cohort Study is a comprehensive historical cohort study on Sardasht chemical victims' population which was designed to find out the long-term complications of sulfur mustard exposure and the basic mechanisms underlying clinical manifestations. This paper describes the design and methodology of Sardasht-Iran Cohort Study.

**Methods:** In Sardasht-Iran Cohort Study, 500 individuals including 372 subjects from Sardasht, as the exposed group, and 128 subjects from Rabat, as the unexposed age-matched control group were evaluated. The exposed group was divided into two groups based on the severity of clinical complications at the time of exposure. Different samples including blood, sputum, saliva, tear, urine, and semen were collected for immunologic, hematologic, biochemical, and other laboratory analysis. Data were gathered from medical records, clinical examinations, laboratory tests, and questionnaires for psychological and lifestyle situations.

**Conclusion:** The important distinctions setting this study apart from the previous ones are discussed. The Sardasht-Iran Cohort Study provides important information on various aspects of long-term consequences of sulfur mustard exposure.

This database will provide a better position to suggest guidelines for the diagnosis, treatment, and prevention of delayed complications in the patients exposed to sulfur mustard.

*Archives of Iranian Medicine, Volume 12, Number 1, 2009: 5 – 14.*

**Keywords:** Clinical complications • immune responses • inflammation • sulfur mustard  
 • toxicology

### Introduction

Sulfur mustard (SM) [bis-(2-chloroethyl) sulfide] is a powerful irritant, blistering, and alkylating agent that reacts readily with most biologic molecules and affects several organs immediately after exposure.<sup>1-6</sup> Once released into the air, SM can travel long distances by wind and contaminate people over a wide area.

<sup>7,8</sup> The respiratory and gastrointestinal tracts, eyes, skin, bone marrow, and the central nervous system

\*Corresponding author and reprints: Tooba Ghazanfari PhD, Department of Immunology, Medical Faculty, Shahed University, Tehran, Iran. P.O. Box: 14155-7435, Tel: +98-218-896-4792, Fax: +98-218-896-6310

E-mail: ghazanfari@shahed.ac.ir; tghazanfari@yahoo.com  
 Accepted for publication: 16 August 2008

\*\*A full list of authors' affiliations appears at the end the paper.

are the most important target organs affected by SM. The acute tissue injuries of these organs depend on the severity and duration of the exposure and mortality is usually low.<sup>2-4,9</sup> In the long term, the most common medical problems include lesions in the respiratory tract, eyes, and skin.<sup>9-21</sup> There is little information and very few studies aimed at identifying the cellular and molecular mechanisms involved in these complications in humans. Clinical evidence indicates the possible involvement of immune and inflammatory reactions in long-term SM complications.<sup>13,17,18,22-26</sup>

SM was extensively used by the Iraqi forces during the Iraq-Iran war (1980 – 1988).<sup>9-31</sup> To date, more than 100,000 Iranians, both military veterans and civilians, have suffered from the long-term effects of SM exposure.<sup>9-10</sup> Sardasht inhabitants have been victims of SM contamination.<sup>11,12,27</sup> Sardasht is a town in the north-west of Iran close to the Iraqi border. It is located geographically at the latitude of 36° 9' 4.48" and longitude of 45° 29' 10.46". On June 28, 1987, Iraqi air forces attacked Sardasht using seven 250-kg bombs of SM, four of which exploded in the densely-populated residential areas in the central part of the town.<sup>9,11,27-31</sup> Based on the official statistics, the bombardment caused SM exposure in 8025 of the 12,000 residents of the town at that time.<sup>9,11,27-31</sup> From the exposed population, at least 4500 people needed treatment; 3000 were exposed to mild doses of SM and were treated for acute effects on an outpatient basis, while the other 1500 were exposed to higher doses of SM, and developed moderate to severe acute medical complications requiring hospitalization at the time.<sup>27</sup> Most of these treated people, and also some who did not develop acute symptoms at the time of exposure, have clinical problems attributed to the exposure at the present time.

Sardasht-Iran Cohort Study (SICS) is a comprehensive historical cohort study on the basic mechanisms underlying clinical complications caused by SM in Sardasht residents 20 years after exposure. Initiated in June 2006 and still ongoing, this study evaluates the health status, long-term clinical complications, molecular patterns of systemic and local immune responses, inflammation, hematologic and biochemical parameters along with the lifestyle, and psychological situation of SM-exposed chemical victims compared with the unexposed (control) group. This paper describes the design and

methodology used in the study.

## Patients and Methods

### Objectives

The aims of this study were to study:

- The health status of SM-exposed people;
- The long-term clinical complications of SM exposure;
- The cellular and molecular patterns, particularly immunologic and inflammatory parameters related to SM long-term complications;
- The comparison and association between the early and late complications;
- The association between clinical complications, lifestyle, psychological situations, and cellular and molecular parameters;
- The impact ratio of each factor in long-term complications; and
- The potential biomarkers and noninvasive surrogate markers of SM-related clinical complications.

### Study organization

The study was carried out with the collaboration of more than 100 investigators from 10 leading medical universities and research centers in Iran. The study investigators were organized into four coordinating groups including: 1) clinicians, 2) basic scientists and their affiliated laboratories, 3) biostatisticians and data analysts, and 4) support and executive personnel. Details of the centers, principal investigators, other executive, research and clinical personnel, and their affiliations are given in Appendix 1.

### Study design

#### Sample size

Among the variables of the present research, cytokines and immunoglobulins have more variations. Since there was no evidence on serum cytokines of chemical victims, the sample size was calculated with immunoglobulin G (IgG) levels. According to Mahmoudi et al.,<sup>26</sup> the mean±SD of IgG in chemically -exposed veterans (n=40) and control group (n=35) was 1438.6±486.1 and 1140.0±244.2 (mg/mL), respectively. Thus, the 95% confidence interval (CI) for IgG difference ( $\mu_2 - \mu_1$ ) is 127.6 to 469.6. In addition, a 95% CI for variance proportion ( $\sigma_1^2 / \sigma_2^2$ ) is 2.1 to 7.4.

In the study by Mahmoudi et al.,<sup>26</sup> the variance

observed in the chemically-exposed group was more than that in the control group; so, the present study was designed to be unbalanced and thus the exposed group had more participants than the control group.

For a type I error ( $\alpha$ ) equal to 0.05, power of analysis of 0.95, type II error ( $\beta$ ) of 0.05 and a variance proportion ( $k = \sigma_1^2 / \sigma_2^2$ ) of 3, the lower band of the CI was chosen as the difference between two groups ( $\Delta = \mu_2 - \mu_1$ ), i.e., 127.6. Then, two groups sample sizes, accordingly  $F_1$  and  $F_2$ , were 351 and 117 in case and control groups.<sup>32</sup>

$$n_1 = (s_1^2 / k + s_2^2) \times (\varphi(1 - \frac{\alpha}{2}) + \varphi(1 - \beta))^2 / \Delta^2$$

(F<sub>1</sub>)

$$n_2 = (s_1^2 + ks_2^2) \times (\varphi(1 - \frac{\alpha}{2}) + \varphi(1 - \beta))^2 / \Delta^2$$

(F<sub>2</sub>)

### Participants

The participants in this study were recruited from Sardasht (exposed) and Rabat (unexposed) residents. The exposed group was selected from the male individuals of Sardasht exposed to SM 20 years ago based on the documents in the medical records verified by the Medical Committee of the Foundation of Martyr and Veterans Affairs. In the medical records, each victim has a medical file with a numeric code. The participants were selected by systematic random sampling method<sup>33</sup> from the chemical victims' list; since the ratio of sample size to records was 0.1, each sample was selected from every 10 records. The unexposed control group was enrolled from Rabat; these participants represented the exposed group from all aspects except exposure to SM. Rabat is a town located 15 kilometers away from Sardasht. Both towns have similar geographical situations and weather conditions. They have Kurdish populations with the same religion, culture,

language, and nutritional habits. The control sample included males selected by systematic random sampling<sup>33</sup> from the list of latest demographic households' statistics at the local health center. They were matched with the exposed group by age considering the inclusion and exclusion criteria.

The inclusion and exclusion criteria for the study are summarized in Table 1. The age range covered by the study was 20 – 60 years. The minimum age of 20 years was chosen because this age includes individuals who were newborns at the time of exposure. The elderly persons over 60 also were excluded to avoid unintended results due to the decline of immune responses of elderly people. In order to avoid any drug interference, exposed participants taking systemic immunosuppressive drugs were excluded from the study.


After a few field trips to Sardasht and Rabat, the research team made a complete list of addresses and phone numbers of selected individuals. The subjects were then contacted by phone, and invited for a brief medical screening by clinicians to apply inclusion and exclusion criteria.

Having studied the medical records, chemical victims were categorized in two major subgroups based on the severity of the clinical problems at the time of exposure: 1) hospitalized: victims who had moderate to severe problems at the time of exposure and were hospitalized in major cities in Iran or sent abroad for treatment, and 2) non-hospitalized: patients who had subclinical or mild problems at the time of exposure and were treated for acute effects on an outpatient basis.

Based upon the severity of early clinical manifestations documented following SM exposure and the duration of hospitalization recorded in the medical documents, the hospitalized group (Group 1) could be further categorized into subgroups. In both exposed and control groups, those with certain clinical complications at the time of study, were divided

**Table 1.** Inclusion and exclusion criteria.

|   |
|---|
| Inclusion   |
| SM exposure in June 1987 based on medical records (for exposed group) |
| Age: 20 – 60 years  |
| Informed consent  |
| No systemic immunosuppressive medication                              |
| Exclusion   |
| Age < 20 and > 60 years   |
| Current treatment with systemic immunosuppressive drugs               |
| History of systemic disease before exposure based on medical records  |
| Suffering from an acute infectious disease at the time of sampling    |
| Disinclination to continue participation                              |



**Figure 1.** Flowchart illustrating study group classification.

into different categories based on results of clinical assessments (Figure 1).

All tests were carried out free of charge and participants were at liberty to leave the project any time they wish. For the subjects with acute clinical signs, proper clinical modalities were undertaken as necessary.

#### **Data collection**

The outcome variables collected from four sources included:

#### **Data in medical records**

Medical records of the exposed individuals in the Foundation of Martyr and Veterans Affairs of Sardasht were studied by physicians. Important data such as the clinical manifestations at the time of exposure, date and duration of hospitalization, distance from the nearest site of chemical bomb explosion, all past and current medications, and other relevant information were collected.

#### **Questionnaire variables**

All the participants were evaluated regarding their socio-demographic information, medical and family history, medications, anthropometric measurements, resting blood pressure, heart rate,

and any sign or symptom of acute infectious diseases. Standard questionnaires related to psychosocial factors, lifestyle (physical activity, stress management, and smoking habits), sleep quality, and healthcare services were administered by psychiatrists, clinical psychologists, health educators, and nurses. Name and purpose of questionnaires and some of their references are given in Table 2.<sup>34-51</sup> Other details of questionnaire design and validation will be reported in next papers.

#### **Clinical evaluation**

All participants were visited by clinicians and their respiratory functions were measured by spirometry under the supervision of a trained nurse. Respiratory signs and symptoms were evaluated by the experienced consultants of the research team. Special ophthalmic variables related to ocular problems including the patients' complaints were evaluated using slit-lamp biomicroscopy, and direct and indirect ophthalmoscopy; and then reports were filed by an ophthalmologist.

Using a predefined protocol, the patients' skin complications were documented by dermatologists. The severity of complications in

**Table 2.** Name and aims of the lifestyle and psychological questionnaires.

| Name   | Aim   | Assessor or supervisor                   | Reference                      |
|--------|---|--|--------------------------------|
| DASS   | Depression, Anxiety Stress Scale  | To assess Depression, Anxiety and Stress | Clinical psychologist<br>34–38 |
| SCL-90 | Symptom Checklist 90  | Assessment of psychiatric symptoms       | Psychiatrist<br>39–41          |
| PSQI   | Pittsburg Sleep Quality Index   | To assess sleep quality                  | Nurse<br>42–45                 |
| DSM-IV | Diagnostic and Statistical Manual of Post-traumatic Stress Disorders, 4th edition | To assess post-traumatic stress disorder | Psychiatrist<br>46             |
| CS-R   | Cope Scale Revised  | To assess stress coping strategies       | Clinical psychologist<br>47,48 |
| GPAQ   | Global Physical Activity Questionnaire  | To assess physical activity              | Health educator<br>49–52       |

respiratory tract, skin and eyes was graded as normal, mild, moderate, or severe based on the criteria verified by the Medical Committee of the Foundation of Martyr and Veterans Affairs.<sup>4,9</sup> Clinical examination findings are analyzed for both primary and second-dary diagnoses among general ICD-9 medical condition categories.<sup>52</sup> In case of any physical or laboratory evidence of disease, such as cardiovascular or rheumatologic diseases, the specific diagnostic tests were carried out.

#### **Laboratory procedures and specimen collection**

Serum, urine, tear, saliva, and sputum samples were collected in aliquots and kept frozen at -70°C for the detection of cytokines, inflammatory and oxidative stress mediators, hematologic and biochemical factors, hormones, and other laboratory analyses. Semen samples were also collected for semen analysis. Phenotypic characterization of immune cells was done by flowcytometry on ethylene diamine tetraacetic acid (EDTA)-treated blood. Functional characterization of cytokine patterns was performed on heparinized venous blood. Blood cell culturing with and without mitogen, CBC, and total urine tests were carried out immediately after sampling. DNA and RNA extractions were carried out and saved. A DNA bank card was also issued for future genetic studies. Skin biopsy was performed for 50 patients who had moderate to severe dermal lesions. Some of the major laboratory variables are shown in Table 3.

#### **Data entry**

Data were entered in database sheets designed for this purpose. All data were then rechecked. Missing data were replaced with *hot deck* single imputation method. In this method, a given subject's missing record was imputed by simply

selecting from sample members with matching other records.<sup>53</sup>

#### **Ethical approval**

The research protocol of the study was approved by the Board of Research Ethics in the Janbazan Medical and Engineering Research Center (JMERC) and Shahed University. An informed written consent was obtained from all the subjects involved in the study.

#### **Data analysis strategy**

To achieve the study goals, data were considered from both clinical and statistical viewpoints. To show the relationship between the basic and clinical findings, association analysis (parametric and nonparametric correlation coefficient) were used. To compare basic and clinical variables in several groups from the retrospective or current status, nonparametric comparison tests such as Kruskal-wallis and Mann-Whitney were used.

One of the important goals of this study was to determine the variables predicting a group of objects and to distinguish between case and control groups. To achieve this purpose, data mining methods, processes by which one discovers the unknown information from large data sets, were used. These methods include association's analysis, clustering, factor analysis, classification tree, and special regression.

To extract important immunologic factors in the exposed group, factor analysis was used for data reduction, and then new factors were applied instead of variables in logistic regression.

In addition, a classification tree was employed to predict the membership of objects in the classes of a response variable (exposed and unexposed to SM) from their measurement on several predictor

**Table 3.** Laboratory variable lists.

| Hematology, biochemistry, and hormones | Cytokines, chemokines, and inflammatory markers | Immunoglobulins and autoantibodies | Cell counts and CD markers |
|--|---|------------------------------------|----------------------------|
| RBC                                    | IL-1 $\alpha$                                   | IgM                                | WBC                        |
| HGB                                    | IL-1 $\beta$                                    | IgE                                | Polymorph %                |
| HCT                                    | IL-1Ra  | IgA                                | Lymphocyte %               |
| PLT                                    | IL-2  | IgG                                | Monocyte %                 |
| RDW                                    | IL-4  | IgG1                               | Eosinophil %               |
| MCH                                    | IL-6  | IgG2                               | Basophil %                 |
| MCV                                    | IL-8  | IgG3                               | CD45+CD3+ cells            |
| MCHC                                   | IL-10   | IgG4                               | CD3+CD4+ cells             |
| MPV                                    | IL-12   |                                    | CD3+CD8+ cells             |
| FBS                                    | IL-17   | Anti-DNA                           | CD45+CD19+ cells           |
| BUN                                    | IL-18   | Antinuclear Ab                     | CD16/56+ cells             |
| Creatinine                             | IL-18 BP  |                                    | CD4+/CD25+ cells           |
| Uric acid                              | IFN $\gamma$                                    |                                    | CD3+/HLA-DR+ cells         |
| Cholesterol                            | TGF- $\beta$                                    |                                    | CD45+/CD14+ cells          |
| Triglyceride                           | TNF- $\alpha$                                   |                                    | CD4+/CD8+ ratio            |
| Calcium                                | CX3L1   |                                    |                            |
| Phosphorus                             | Fas-L   |                                    |                            |
| Bilirubin total                        | MMP9  |                                    |                            |
| Bilirubin direct                       | TIMP1   |                                    |                            |
| ALT (SGOT)                             | TIMP2   |                                    |                            |
| AST (SGPT)                             | TIMP2   |                                    |                            |
| ALP                                    | GM-CSF  |                                    |                            |
| LDH                                    | RANTEST   |                                    |                            |
| Peripheral blood smear                 | CCL 2/MCP - 1                                   |                                    |                            |
| FSH                                    | sICAM - 1                                       |                                    |                            |
| LH                                     | sE-Selectin                                     |                                    |                            |
| Prolactin                              | sL-Selectin                                     |                                    |                            |
| Testosterone                           | sP-Selectin                                     |                                    |                            |
| T3                                     | CRP   |                                    |                            |
| T4                                     | RF  |                                    |                            |
| TSH                                    | Substance P                                     |                                    |                            |
| PTH                                    | LAG-3   |                                    |                            |
| FT3,FT4                                | Nitric oxide                                    |                                    |                            |
| Thyroglobulin                          | C3, C4 (complement)                             |                                    |                            |
| Semen analysis                         |   |                                    |                            |

variables.

To make new clusters from immunologic variables, cluster analysis which is a data mining approach that partitions a large set of data objects into homogeneous groups was applied.

For the other goals of the current study, a risk scoring system was employed to determine the optimal cut-off point for detection groups (exposed and unexposed to SM) of new cases and also the receiver-operating characteristic curve (ROC curve) was calculated by plotting the sensitivity of the test versus the false-positive rate (1-specificity). The cut-off point was selected to maximize the true-positive rate while minimizing the false-positive rate. In this method, the risk equation was determined by the stepwise multiple logistic regression analysis.

### Sample characteristics

There were no significant differences in terms of age, body mass index, marital status, and

smoking habits between the control and exposed groups. Total sample size of the study, the sample size of each study group, their age distributions, and demographic information of the population under study are shown in Table 4.

### Discussion

Various studies have been performed on short- and long-term clinical manifestations of chemical victims,<sup>3,4,9,11,12,15,27,15-21</sup> but there are few studies discussing the basic mechanisms of long-term clinical manifestations of SM exposure.<sup>22-26</sup> Our knowledge regarding cellular and molecular mechanisms involved in these disorders is still incomplete. Long-term complications of SM can come from the different routes following exposure: paraclinical changes up to clinical and psychological complication aspects. A historical cohort study was designed to evaluate the clinical outcomes along with the basic mechanisms of the

**Table 4.** Demographic information of the study population.

| Variables                            | Control     | Exposed         |              | P value |
|--------------------------------------|-------------|-----------------|--------------|---------|
|                                      |             | Nonhospitalized | Hospitalized |         |
| Sample size                          | 128         | 203             | 169          |         |
| Age (mean ± SD)                      | 41.7±9.8    | 43.4±10.8       | 44.4±10.7    | 0.103   |
| Age group (year)                     | 20 to 29    | 15(11.7%)*      | 24(11.8%)*   | 0.422   |
|                                      | 30 to 39    | 43(33.6%)       | 52(25.6%)    |         |
|                                      | 40 to 49    | 37(28.9%)       | 60(29.6%)    |         |
|                                      | 50 to 60    | 33(25.8%)       | 67(33.0%)    |         |
| Body mass index (Kg/m <sup>2</sup> ) | ≤25         | 52(40.6%)       | 78(38.4%)    | 0.954   |
|                                      | 25 – 30     | 54(42.2%)       | 94(46.3%)    |         |
|                                      | ≥30         | 22(17.2%)       | 31(15.3%)    |         |
| Marital status                       | Not married | 10 (7.8%)       | 17 (8.4%)    | 0.901   |
|                                      | Married     | 118 (92.2%)     | 186 (91.6%)  |         |
| Smoking                              | Yes/Quitted | 29 (22.7%)      | 49 (24.1%)   | 0.946   |
|                                      | Never       | 99 (77.3%)      | 154 (75.9%)  |         |

\*= Data presented as count (percentage).

outcomes along with the basic mechanisms of the long-term clinical complications and psychological and lifestyle situations. Since clinical evidence indicates the probable involvement of immunologic and inflammatory mechanisms,<sup>22–26</sup> molecular patterns of systemic and local immune and inflammatory responses were evaluated in this study. Psychological parameters, lifestyle, and socioeconomic situations were evaluated through questionnaires. In this way, the impact ratio of each risk factor was determined. This paper describes the design and methodology used in the study. Several important distinctions, setting this study apart from previous ones are:

- This was the first study that evaluated numerous factors including different clinical consequences, various basic and molecular mechanisms, lifestyle parameters, and psychological factors from a comprehensive viewpoint.
- In previous studies, the samples were selected based on their current problems. But in this study, the samples were selected based on the severity of signs and symptoms at the exposure time and followed-up for their current problems.
- The effect of many other confounding variables were reduced since chemical victims of this study came from the same geographical region, lived in similar socioeconomic conditions, and had similar demographic features.
- The exposed group in this study was exposed at the same time by the identical composition of

SM whereas previous studies have been done on veterans exposed by different chemical warfare compositions at various times.

- Another characteristic of this study was the availability of the recorded data, extracted from the patient's medical records regarding clinical status at the time of exposure. This database provided good baseline information for our historical cohort study.
- The participation of a good matched control group was another distinction of this study. The control group participants in this study came from Rabat, a town close to Sardasht and the only difference between them was SM exposure. The population of both towns has similar ethnic, cultural, and geographical situations. They also have similar levels of other stressors, i.e., both towns were exposed to high intensity conventional warfare throughout the Iraq-Iran war, but only Sardasht was exposed to chemical weapons.
- One of the important aims of this study was to find out the potential biomarkers that are very important to the evaluation of clinical trials. The assessment of numerous types of biomarkers in this study makes it possible to achieve a surrogate marker for clinical endpoints.

The above-mentioned criteria of this research make it a unique and unprecedented study that covers the long-term complications of SM exposure, the comparison of the early and late complications, the health status of the people by

focusing on the molecular and immunologic parameters, and potential biomarkers and surrogate endpoints. We hope that the results of this study will provide important information on the basic mechanisms of the long-term clinical complications of SM exposure. Furthermore, we will be better positioned to suggest guidelines for the diagnosis, more effective treatment, and the prevention of the long-term complications following SM exposure. In addition, this research lays the groundwork for further research on the various aspects of SM-related problems.

### Acknowledgment

The present study was funded by the Iranian Foundation of Martyr and Veterans Affairs, Ministry of Health and Medical Education, Shahed University, and Janbazan Medical and Engineering Research Center (JMERC).

We would like to thank all the participants who took part in this study and dedicated their time and different specimens very kindly. We also kindly thank the kind and cooperative people of Sardasht and Rabat as well as the helpful officials of Sardasht region, particularly the Foundation of Martyr and Veterans Affairs, Sardasht Health-Care System, and Health Center of Rabat. We also kindly thank Dr. Mohsin-Reza Heidari for his helpful comments and editing of the manuscript.

### References

- Evison D, Hinsley D, Rice P. Chemical weapons. *Br Med J*. 2002; **324**: 332 – 335.
- Bullman T, Kang H. A fifty- year mortality follow-up study of veterans exposed to low level chemical warfare agent, mustard gas. *Ann Epidemiol*. 2000; **10**: 333 – 338.
- Momeni AZ, Enshaeih S, Meghdadi M, Amindjavaheri M. Skin manifestations of mustard gas. A clinical study of 535 patients exposed to mustard gas. *Arch Dermatol*. 1992; **128**: 775 – 780.
- Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. *Fundam Clin Pharmacol*. 2005; **19**: 297 – 315.
- Bignold LP. Alkylating agents and DNA polymerases. *Anticancer Res*. 2006; **26**: 1327 – 1336.
- Hassan ZM, Ebtekar M, Ghanei M, Taghikhani M, Noori Dalooi MR, Ghazanfari T. Immunobiological consequences of sulfur mustard contamination. *Iran J Allergy Asthma Immunol*. 2006; **5**: 101 – 108.
- Aasted A, Darre E, Wulf HC. Mustard gas: clinical, toxicological, and mutagenic aspects based on modern experience. *Ann Plast Surg*. 1987; **19**: 330 – 333.
- Geraci MJ. Mustard gas: imminent danger or eminent threat? *Ann Pharmacother*. 2008; **42**: 237 – 246.
- Khateri S, Ghanei M, Keshavarz S, Soroush M, Haines D. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. *J Occup Environ Med*. 2003; **45**: 1136 – 1143.
- Kehe K, Szinicz L. Medical aspects of sulphur mustard poisoning. *Toxicology*. 2005; **214**: 198 – 209.
- Khateri S, Ghanei M, Soroush M, Haines D. Effect of mustard gas exposure in pediatric patients: long-term health status of mustard-exposed children, 14 years after chemical bombardment of Sardasht. Sofia: Publishing House of the Union of Scientists in Bulgaria; 2005.
- Ghanei M, Aslani J, Khateri S, Hamadanizadeh K. Public health status of the civil population of Sardasht 15 years following large-scale wartime exposure to sulfur mustard. *J Burns Surg Wound Care*. 2003; **2**: 7 – 18.
- Javadi MA, Yazdani S, Sajjadi H, Jadidi K, Karimian F, Einollahi B, et al. Chronic and delayed-onset mustard gas keratitis: report of 48 patients and review of the literature. *Ophthalmology*. 2005; **112**: 617 – 625.
- Bijani K, Moghadamnia AA. Long-term effects of chemical weapons on respiratory tract in Iraq-Iran war victims living in Babol (north of Iran). *Ecotoxicol Environ Saf*. 2002; **53**: 422 – 424.
- Javadi MA, Yazdani S, Kanavi MR, Mohammadpour M, Baradaran-Rafiee A, Jafarinasab MR, et al. Long-term outcomes of penetrating keratoplasty in chronic and delayed mustard gas keratitis. *Cornea*. 2007; **26**: 1074 – 1078.
- Zarchi K, Akbar A, Naieni KH. Long-term pulmonary complications in combatants exposed to mustard gas: a historical cohort study. *Int J Epidemiol*. 2004; **33**: 579 – 581.
- Ghanei M, Harandi AA. Long-term consequences from exposure to sulfur mustard: a review. *Inhal Toxicol*. 2007; **19**: 451 – 456.
- Balali-Mood M, Hefazi M, Mahmoudi M, Jalali E, Attaran D, Maleki M, et al. Long-term complications of sulphur mustard poisoning in severely intoxicated Iranian veterans. *Fundam Clin Pharmacol*. 2005; **19**: 713 – 721.
- Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. *Chest*. 1997; **112**: 734 – 738.
- Emadi SN, Hosseini-Khalili A, Soroush MR, Davoodi SM, Aghamiri SS. Mustard gas scarring with specific pigmentary, trophic, and vascular characteristics (case report, 16-year post-exposure). *Ecotoxicol Environ Saf*. 2008; **69**: 574 – 576.
- Firooz A, Komeili A, Dowlati Y. Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas. *J Am Acad Dermatol*. 1999; **40**: 646 – 647.
- Emad A, Rezaian GR. Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. *Chest*. 1999; **115**: 1346 – 1351.
- Emad A, Rezaian GR. Characteristics of bronchoalveolar lavage fluid in patients with sulfur mustard gas-induced asthma or chronic bronchitis. *Am J Med*. 1999; **106**: 625 – 628.
- Emad A, Emad V. Elevated levels of MCP-1, MIP-[alpha], and MIP-1[beta] in the bronchoalveolar lavage (BAL) fluid of patients with mustard gas-induced pulmonary fibrosis. *Toxicology*. 2007; **240**: 60 – 69.



- 25 Emad A, Emad Y. Increased granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) levels in BAL fluid from patients with sulfur mustard gas-induced pulmonary fibrosis. *J Aerosol Med.* 2007; **20**: 352 – 360.
- 26 Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. *Int Immunopharmacol.* 2005; **5**: 1479 – 1485.
- 27 Foroutan A. *Medical Experiences of Iraq's Chemical Warfare.* Tehran: Baqiyatallah University of Medical Sciences; 2003: 179 – 188.
- 28 United Nations Security Council. Report of the mission dispatched by the Secretary General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq. Jun. 29, 1987. S/18953. New York, USA, United Nations; 1987.
- 29 United Nations Security Council. Report of the mission dispatched by the Secretary General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq. Jun.30, 1987. S/18956. New York, USA, United Nations; 1987.
- 30 United Nations Security Council. Report of the mission dispatched by the Secretary General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq. Jul. 6, 1987. S/18966. New York, USA, United Nations; 1987.
- 31 United Nations Security Council. Report of the mission dispatched by the Secretary General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq. Jul. 30, 1987. S/19006. New York, USA, United Nations; 1987.
- 32 Rosner B. *Fundamentals of Biostatistics.* 3rd ed. Boston, Mass.: PWS-Kent Pub. Co.; 1990: 275.
- 33 Levy PS, Lemeshow S. Sampling of population; methods and applications. New York, USA: John Wiley and Sons; 1991.
- 34 Lovibond SH, Lovibond PF. *Manual for the Depression Anxiety Stress Scales.* 2nd ed. Sydney: Psychology Foundation; 1995.
- 35 Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. *Behav Res Ther.* 1997; **35**: 79 – 89.
- 36 Psychology Foundation of Australia: Persian translations of the DASS, Pirmoradi Persian translation (in Persian). Available from: URL: <http://www2.psy.unsw.edu.au/groups/dass//Persian/Pirmo-radi.htm>. [Cited 2008/03/01]
- 37 Lovibond PF, Lovibond SH, The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. *Behav Res Ther.* 1995; **33**: 335 – 343.
- 38 Taylor R, Lovibond PF, Nicholas MK, Cayley C, Wilson PH. The utility of somatic items in the assessment of depression in patients with chronic pain: a comparison of the Zung Self-Rating Depression Scale and the Depression Anxiety Stress Scales in chronic pain and clinical and community samples. *Clin J Pain.* 2005; **21**: 91 – 100.
- 39 Derogatis LR. *SCL-90-R Symptom Checklist 90-R, Administration, Scoring, and Procedure Manual.* 3rd ed. Baltimore: Clinical Psychometric Research; 1994.
- 40 Salimi SH, Azad-Marzabadi E, Karaminia R, Mirzamani SM, Hosseini-Sangtrahani SA. Being a wife of a veteran with psychiatric problem or chemical warfare exposure: a preliminary report from Iran. *Iran J Psychiatry.* 2006; **1**: 65 – 69.
- 41 Mirzai R. *Standardizing and validating the SCL-90-R in Iran.* Master's thesis, Tehran University, Tehran, Iran; 1979.
- 42 Kachuee H, Ameli J, Taheri S, Assari S, Riahipour F, Khedmat H, et al. Sleep quality and its correlates in renal transplant patients. *Transplant Proc.* 2007; **39**: 1095 – 1097.
- 43 Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 1989; **28**: 193 – 213.
- 44 Shahidi J, Khodabakhshi R, Yahyazadeh SH, Amini M, Nosrati H. Quality of sleep in cancer patients: evidences from Persian Translation of Pittsburgh Sleep Quality Index. *Austral Asian J Cancer.* 2007; **6**: 165 – 168.
- 45 Pourafkary N, Arfai A, Dadashzadeh H, Gaemmgami J. A Comparative study on the prevalence of sleep disturbances in psychiatric disorder and general population in Tabriz. *MJTUMS.* 2005; **64**: 28 – 33.
- 46 Breslau N, Peterson EL, Kessler RC, Schultz LR. Short screening scale for DSM-IV post-traumatic stress disorder. *Am J Psychiatry.* 1999; **156**: 908 – 911.
- 47 Caraver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically-based approach. *J Pers Soc Psychol.* 1989; **56**: 267 – 283.
- 48 Ebrahimi A, Bolhari J, Zolfaghari F. Stress coping strategies and social support in depressive Veterans with spinal cord injury [in Persian]. *Iranian J Psychiatr Clin Psychol. [Andisheh va Raftar].* 2002; **8**: 40 – 48.
- 49 Department of Chronic Diseases and Health Promotion Surveillance and Population-Based Prevention (World Health Organization) Global Physical Activity Questionnaire (GPAQ): Analysis Guide, [Cited 2008/03/01], Available from: URL: [http://www.who.int/chp/steps/resources/GPAQ\\_Analysis\\_Guide.pdf](http://www.who.int/chp/steps/resources/GPAQ_Analysis_Guide.pdf)
- 50 Armstrong T, Bull F. Development of the World Health Organization Global Physical Activity Questionnaire (GPAQ). *J Public Health.* 2006; **14**: 66 – 70.
- 51 GPAQ. Global Physical Activity Questionnaire (version 2.0). Available from: URL: [http://www.who.int/cgp/steps/resources/GPAQ\\_analysis\\_guide.pdf](http://www.who.int/cgp/steps/resources/GPAQ_analysis_guide.pdf) [Accessed date: 15 March, 2008]
- 52 Kroenke K, Spitzer RL, Williams JB, Linzer M, Hahn SR, deGruy FV 3rd, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. *Arch Fam Med.* 1994; **3**: 774 – 779.
- 53 Reilly M. Data analysis using hot deck multiple imputation. *The Statistician.* 1993; **42**: 307 – 313.

**\*\*Authors' affiliations:** <sup>1</sup>Department of Immunology, Shahed University, Tehran, <sup>2</sup>Immunoregulation Research Center, Shahed University, Tehran, <sup>3</sup>Department of Biostatistics, Tarbiat Moddarres University, Tehran, <sup>4</sup>Baqiyatallah University of Medical Sciences, Tehran, <sup>5</sup>Janbazan Medical and Engineering Research Center (JMERC), Tehran, <sup>6</sup>Department of Immunology, Tarbiat Moddarres University, Tehran, <sup>7</sup>Department of Physiology, Shaheed Beheshti University of Medical Sciences, Tehran, <sup>8</sup>Department of Physiology, Shahed University, Tehran, <sup>9</sup>Ophthalmology Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, <sup>10</sup>Medical Research Center, Shahed University, Tehran, <sup>11</sup>Endocrine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, <sup>12</sup>Research Center of Chemical Injuries, Baqiyatallah University of Medical Sciences, Tehran, <sup>13</sup>Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, <sup>14</sup>Department of Ophthalmology, Shahed University, Tehran, <sup>15</sup>Department of Oncology and Hematology, Shahed University, Tehran, <sup>16</sup>Department of Internal Medicine, Shahed University, Tehran, <sup>17</sup>Department of Pathology, Shahed University, Tehran, <sup>18</sup>Department of Cardiology, Shahed University, Tehran, <sup>19</sup>Department of Health, Ilam University of Medical Sciences, Ilam, <sup>20</sup>Department of Immunology, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, <sup>21</sup>Department of Rheumatology, Shahed University, Tehran, <sup>22</sup>Department of Dermatology, Shahed University, Tehran, <sup>23</sup>Department of Immunology, Isfahan University of Medical Sciences, Isfahan, <sup>24</sup>Department of Immunology, Pasteur Institute of Iran, Tehran, <sup>25</sup>Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, <sup>26</sup>Department of Psychology, Shahed University, Tehran, <sup>27</sup>Chemical Victims' Clinic of Sardasht, Sardasht, West Azarbaijan Province, Iran.

## **\*Appendix 1**

### Sardasht-Iran Cohort Study (SICS) research team and their center

#### **Shahed University**

Tooba Ghazanfari PhD, Roya Yaraee PhD, Mohammad R. Vaez-Mahdavi PhD, Sakine Moaiedmohseni MD MPH, Hassan Ghasemi MD, Mohammad R. Jalali-Nadoushan PhD, Jaleedin Shams MD, Shahryar Pourfarzam MD, Faramarz Fallahi MD, Shamsa Shariat- Panahi MD, Athar Moin MD, Ghasem Azimi MD, Mohammad E. Yarmohammadi MD, Gholamhosein Ghaedi MD, Parviz Owlia PhD, Ali Davati MD, Rasool Roshan MD, Batol Rahmati PhD, Hassan Salimi PhD, Ashrafe Piraste PhD, Zahra Kiasalari PhD, Fariba Khoshzaban PhD, Reza Afshar MD, Mohammad- Mehdi Naghizadeh MSc, Behzad Jodeiry MD, Tahere Zandieh PhD, Khadije Mohammadi MSc, Davood Jamali BSc, Basir Malekpoor MSc, Akbar Sha-Ali BSc, Farideh Danyali MSc, Zarin Sharifinia MSc, Arezou Kermani-Jalilvand MSc, Ali Rahm-Ghasemian MD, Fateme Mohamadi MD, Sara Amiri MSc, Mojgan Kardar MSc, Marzieh Eghtedardoost MSc, Hoda Hakimzade MSc

#### **Janbazan Medical and Engineering**

##### **Research Center (JMERC)**

Mohammad-Reza Soroush MD, Shahryar Khateri MD, Reza Amini MD, Naser Emadi MD, Farahnaz Falahati MD

#### **Tarbiat Moddarres University**

Soghrot Faghihzadeh PhD, Zuhair Mohammad Hassan PhD, Massoumeh Ebtekar PhD, Zeinab Ghazanfari MSc, Saeid Tebyanian MSc, Mahsa Saadati MSc, Marjan Mansourian MSc, Samaneh Hosseinzadeh MSc  
Shohreh Jalaei PhD

#### **Baqiyatallah University of Medical Sciences**

Mostafa Ghanei MD, Mahmood Babai MD, Javad Merasizadeh MD, Seyyed-Masoud Davoudi MD, Yunes Panahi PhD, Mohsin-Reza Heidari PhD, Gholamreza Karami MD

#### **Shaheed Beheshti University of Medical Sciences**

Abbas Foroutan MD PhD, Mohammad- Ali Javadi MD, Fereidoun Azizi MD, Mohammad Ghassemi-Broumand MD, Farid Zaeri PhD

#### **Medical Biology Research Center of Kermanshah University of Medical Sciences**

Ali Mostafaie PhD, Maryam Chalabi MSc, Sara Kiani BSc, Fariba Ghanbari BSc, Shahram Parvaneh BSc

#### **Pasteur Institute of Iran**

Amina Kariminia PhD, Soheila Ajdary PhD, Fereidoun Mahboudi PhD, Nayere Askari PhD, Hayede Darabi MD, Frahade Riazi PhD student

#### **Immunology Research Center of Mashhad University of Medical Sciences**

Mahmood Mahmoodi PhD, Maryam Rastin PhD, Shahrzad Zamani MSc, Nafise Tabasi MSc

#### **Isfahan University of Medical Sciences**

Abbas Rezaei PhD, Alireza Andalib PhD, Marjan Gharagozloo PhD, Zahra Giasi MSc

#### **Chemical Victims' Clinic of Sardasht**

Nastaran Habibi -Ashtyani MD, Sulayman Ghaderi MSc, Faramarz Heidari MD, Reza Tolou'ei MD, Shahla Mohamadpanahi MD, Rojhan Ghaderi MD, Ameneh Mola'ian MD, Fatah Ma'roufi- Aghdam, Seddiq Ma'roufipour, Mohsen Mowafiqhi MSc, Sara Alipour BSc, Maryam Barzigar BSc, Golaleh Shamami BSc, Shadi Mahmoudnejhad BSc, Altoun Meykhasteh BSc

#### **Other Centers**

Ali Montazeri PhD, Sussan K. Ardestani PhD, Zohreh Farhnejad PhD, Parisa Mohammadi PhD, Ahya Abdi PhD, Frouzandeh Jalilvand MSc